Nav: Home

Now entering 'the valley of death'

January 12, 2017

From reading and hearing news accounts, the general public has a vague impression that some things are amiss with the pharmaceutical industry -- one word: Epipens. But few might consider it an industry in a state of collapse.

Michael Kinch tries to convince otherwise in "A Prescription for Change," his history and review of the industry. Kinch is the associate vice chancellor and director of the Center for Research Innovation in Biotechnology at Washington University in St. Louis, and he brings to this book (University of North Carolina Press) many decades of research and harrowing personal experience with pharma.

The book starts with some classic tales of the struggle to make sure drugs weren't poisons and actually did what they were said to do. One early antibiotic, for example, was mixed in a sweet syrup whose main ingredient was antifreeze: 106 died, mostly children.

The pace quickens as the struggle between innovation and regulation becomes fiercer. The industry spins off, Kinch notes, into new territories, such as patent extensions, me-too drugs, generics, pay-for-delay, orphan drugs and compendium expansion.

Companies found ways to game the system by gaining FDA approval for an orphan drug under favorable terms and then conducting a small clinical trial that would allow the drug to be approved for another indication, called "compendium expansion." This was lucrative, Kinch explains, because orphan drugs could command high "price points" without insurance companies squealing, but the expansion drugs made up for the small number of patients with orphan indications.

Kinch repeatedly emphasizes that decisions like these are rational and not based on "dark motivations." And the point of the book is really that the high cost of bringing a new drug to market ($2.6 billion) is largely the unintended consequence of the desire to make sure drugs are safe.

By chapter 10, the author is describing how such high costs led pharmaceutical companies to cut costs, dismantled their own research and development wings but were forced to replenish their drug pipelines by buying one another and then biotechnology start-ups.

Altogether, Kinch says, the biotechnology sector was responsible for more than two-thirds of all new medicines in the past decade.

But Kinch says this finesse is already failing. The number of successful biotech companies peaked at 141 in 2000 and had fallen to 60 by the end of 2014. It is simply easier and less risky for venture capitalists to invest in two guys in a garage writing code, says Kinch, than in a large, complex biotech lab. As a result, the entire industry, Kinch says, may be "fading to black."

To make sure the reader understands the stakes, Kinch mentions three looming crises in drug therapy. One is antibiotic resistance, which, some experts say, will break the surface and come to widespread public notice. in 2017.

A similar problem, but one that has received less attention, is the emergence of resistance to AIDS drugs. One in five AIDS patients had a virus that was resistant to at least one component of the current drug cocktail, Kinch says. Seven of the 10 companies that successfully developed AIDS drugs have dropped research in this area.

And then there is Alzheimer's. Fully 99.6 percent of experimental drugs designed to treat Alzheimer's failed in clinical trials, according to a 2015 report that Kinch cites. Many pharmaceutical companies, not surprisingly, have reduced or completely eliminated programs that had been focused on Alzheimer's disease and other neuroscience indications.

What can be done? To survive the current crisis, Kinch says, "we will need to fundamentally reconsider all aspects of how new medicines are created." To get the ball rolling, he ends his book with a few ideas. For example, he suggests the potential elimination of the requirement for costly Phase III clinical trials.

To those familiar with the history of drug toxicities and side effects, that may seem like an outrageous proposition. But Kinch would argue that it is better than running off the cliff that seems to be in front of us -- hence, the reference to the expression already used in some places around the industry "The Valley of Death."
-end-


Washington University in St. Louis

Related Antibiotic Resistance Articles:

One of the mechanisms of Staphylococcus antibiotic resistance deciphered
The Russian side is represented by Structural Biology Lab (Kazan Federal University) and Institute of Proteins (Russian Academy of Sciences).
Antibiotic-resistance in Tanzania is an environmental problem
WSU study finds that environmental transmission rather than antibiotic use explains the presence of antibiotic-resistant bacteria in people, domestic animals and wildlife.
Stressed-out dust is sharing antibiotic resistance genes
A new Northwestern University study is the first to find that bacteria living in household dust can spread antibiotic resistance genes.
Cause of antibiotic resistance identified
Bacteria can change form in human body, hiding the cell wall inside themselves to avoid detection.
The solution to antibiotic resistance could be in your kitchen sponge
Researchers from the New York Institute of Technology (NYIT) have discovered bacteriophages, viruses that infect bacteria, living in their kitchen sponges.
Antibiotic resistance in spore-forming probiotic bacteria
New research has found that six probiotic Bacillus strains are resistant to several antibiotics.
How bacteria acquire antibiotic resistance in the presence of antibiotics
A new study's disconcerting findings reveal how antibiotic resistance is able to spread between bacteria cells despite the presence of antibiotics that should prevent them from growing.
Five rules to tackle antibiotic resistance
Current efforts to tackle antibiotic resistance are 'not nearly radical enough,' a leading scientist says.
Breaking open the gates of antibiotic resistance
Creating a defect in tRNA molecules could weaken bacteria's two-pronged defense and help make faster-acting antibiotics
Wastewater reveals the levels of antibiotic resistance in a region
A comparison of seven European countries shows that the amount of antibiotic resistance genes in wastewater reflects the prevalence of clinical antibiotic resistance in the region.
More Antibiotic Resistance News and Antibiotic Resistance Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Listen Again: Reinvention
Change is hard, but it's also an opportunity to discover and reimagine what you thought you knew. From our economy, to music, to even ourselves–this hour TED speakers explore the power of reinvention. Guests include OK Go lead singer Damian Kulash Jr., former college gymnastics coach Valorie Kondos Field, Stockton Mayor Michael Tubbs, and entrepreneur Nick Hanauer.
Now Playing: Science for the People

#562 Superbug to Bedside
By now we're all good and scared about antibiotic resistance, one of the many things coming to get us all. But there's good news, sort of. News antibiotics are coming out! How do they get tested? What does that kind of a trial look like and how does it happen? Host Bethany Brookeshire talks with Matt McCarthy, author of "Superbugs: The Race to Stop an Epidemic", about the ins and outs of testing a new antibiotic in the hospital.
Now Playing: Radiolab

Dispatch 6: Strange Times
Covid has disrupted the most basic routines of our days and nights. But in the middle of a conversation about how to fight the virus, we find a place impervious to the stalled plans and frenetic demands of the outside world. It's a very different kind of front line, where urgent work means moving slow, and time is marked out in tiny pre-planned steps. Then, on a walk through the woods, we consider how the tempo of our lives affects our minds and discover how the beats of biology shape our bodies. This episode was produced with help from Molly Webster and Tracie Hunte. Support Radiolab today at Radiolab.org/donate.